Evoq Remedies Share Price Today

Evoq Remedies gets ROC nod to extend FY26 AGM deadline to Oct 30

Evoq Remedies Limited received ROC approval to extend its 16th AGM deadline. New due date for the FY26 AGM is October 30, 2026. Extension granted due to ongoing Corporate Insolvency Resolution Process. Application was filed by the Resolution Professional on September 28, 2026.

Evoq Remedies faces insolvency plea from Harbhole Agrotech

Harbhole Agrotech filed an insolvency application against Evoq Remedies under Section 9 of the IBC, 2016, seeking the initiation of CIRP. The petition was lodged with the NCLT Ahmedabad on April 20, 2026, by the creditor's proprietor, Krushna Kurjibhai Lakkad. Evoq Remedies disclosed the development to the stock exchange on June 10, 2026.

Evoq Remedies reports FY26 loss, auditors flag going concern risk

Evoq Remedies Limited reported a net loss of ₹23.99 lakh for FY26, down from a profit of ₹8.82 lakh in FY25, with revenue rising to ₹2,550.68 lakh. Auditors issued a qualified opinion citing material uncertainty about the company's going concern status due to liquidity issues, unpaid taxes of ₹100.39 lakh, and unconfirmed loans and advances. The company faces SEBI investigation into preferential issue fund usage and litigation for GST and income tax demands totaling ₹842.95 lakh.

Evoq Remedies Reschedules Board Meeting to May 27, 2026 for FY26 Financial Results

Evoq Remedies Limited has rescheduled its Board of Directors meeting from May 14, 2026 to May 27, 2026, at 4:00 P.M. at its Ahmedabad registered office. The meeting, filed under Regulation 29(1) of SEBI (LODR) Regulations, 2015, will consider audited financial results for the half year and year ended March 31, 2026, along with the Auditor's Report.

Evoq Remedies Limited Submits Q4FY26 Compliance Certificate Under SEBI Regulations

Evoq Remedies Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4FY26, covering the period from January 1, 2026 to March 31, 2026. The certificate from RTA Accurate Securities & Registry Private Limited confirms that all dematerialisation processes were completed within regulatory time limits, demonstrating the company's adherence to SEBI guidelines for securities processing and listing requirements.

Evoq Remedies Reports Mixed Half-Year Results Amid Regulatory Scrutiny and Compliance Issues

Evoq Remedies Limited reported revenue of ₹1,175.67 lakhs and profit after tax of ₹5.43 lakhs for the half-year ended September 30. Total assets increased to ₹5,221.50 lakhs. The company faces significant regulatory challenges including a SEBI investigation, failure to implement audit trail software, GST demand of ₹655.03 lakhs, income tax disputes, unconfirmed advances, and non-compliant related party transactions. The auditor, H Thakkar & Co. LLP, has raised concerns about these issues and their potential financial impact.